Xi Jinping Pharmaceuticals: Plans to divest its subsidiary Buddhu Pharmaceuticals into Deep Swap Mai
Protecting women's, children's and family health is an important issue of common concern for the whole society. On the evening of June 9, the company announced that it plans to divest its subsidiary Shandong Shandong Pharmaceutical Shares Ltd. (abbreviated as Shandong Pharmaceutical Co.
, Ltd. ) from the Shenzhen Stock Exchange. According to the announcement, after many years of development, Shenzhen Pharmaceuticals is engaged in the production and development of pharmaceuticals, the company's product structure is rich, covering tablets, capsules, powdered syringes, small-capacity injectors, large-capacity injectors, and a wide range of doses, including generic solutions, nutritional solutions, anti-infectious medicines, cardiovascular medicines, hepatically-sensitive medicines, digestive system medicines, anti-cancer drugs, etc.
The announcement said that Buddhist Pharmaceuticals are investing heavily in improving product quality, breakthrough R&D bottlenecks, expanding market share, increasing technological innovation and R&D investments, and increasing production efficiency. It is anticipated that as technology progresses and demand improves, the field will also open up new areas of development. While Buddhist medicine will mainly be used for non-pharmaceutical products, it will be possible to produce more than 80 products of more than 40 types, including eye ointments, ointments, moisturizers, drops, ear drops, nasal sprays, infusions, etc.
At the same time, Buddhist medicine will make full use of the functionality and advantages of direct capital market financing, expand the channels of financing, improve the efficiency of financing, reduce the cost of financing, and provide shareholders with a higher return on investment. For the general public, it is especially important to establish a scientifically rational health concept. According to the announcement, the divestment will further enhance the company's brand image, business development capacity and level of specialization, allowing the company to integrate resources into drug R&D and production.
In the short term, the company's net profits from the divestment are likely to be diluted, but in the medium term, the divestment will increase its own capital strength, enhance R&D capabilities, further enhance market competitiveness and increase market share, thereby helping to raise the company's overall future profits. The company said that after the divestment was completed, Buddhou Pharmaceuticals will continue to be a controlled subsidiary within the scope of the company's consolidated financial statements, and that the financial condition and profitability of Buddhou Pharmaceuticals will continue to be reflected in the company's consolidated financial statements. For those of you who recommend massaging more children in the spring with these holes, tap through 9 of the most trendy detoxification techniques to master the human body's top 10 health care holes at any given time, over 60 diseases, addiction to alcohol and drinking-related cockroaches social, young people's emotional needs, new displays over the labyrinth of soap brain mechanisms reveal the key protein discoveries that lead to skin aging developers discount promotions?
The next step in the industry is the development of a healthy, well-balanced, socially-transparent acids, which can be a hallmark of an undiagnosed cancer. Point China International Health Service System is continuously monitoring the latest developments in the field of healthcare to provide you with authoritative, reliable information and advice on medical services. If you need further advice on this, please contact authoritative experts via the platform.
